Centessa Pharmaceuticals plc 8-K/A

What Happened
Centessa Pharmaceuticals plc (CNTA) filed an amendment to its Form 8‑K (originally filed Dec 11, 2025) to add an employment agreement dated January 5, 2026 between the company and Mario Accardi. The amendment was filed Jan 7, 2026 and the report was signed by CFO John Crowley on Jan 6, 2026. No other changes were made to the original Form 8‑K.

Key Details

• The filing supplements the Dec 11, 2025 Form 8‑K Item 5.02 (departure/election of directors or certain officers) with the employment agreement for Mario Accardi.
• Employment Agreement dated: January 5, 2026 (filed as Exhibit 99.1).
• Amendment filed with the SEC: January 7, 2026; report signed by John Crowley, Chief Financial Officer, on January 6, 2026.
• The company states no other changes were made to the Original Form 8‑K.

Why It Matters
This amendment completes public disclosure of the terms governing an executive-level appointment noted in the prior 8‑K. For investors, the added employment agreement lets you review the contractual terms (compensation, duties, term, and any change‑of‑control or severance provisions) that can affect governance, executive costs, and potential future expenses. Review Exhibit 99.1 in the amended 8‑K for the full contract details.